SEC Comment Letter 0000000000-26-005506 to Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc.
Date: May 29, 2026 · CIK: 0001708599 · Accession: 0000000000-26-005506
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296166
Letter
May 29, 2026 Steven Ledger Chief Executive Officer Serina Therapeutics, Inc. 601 Genome Way, Suite 2001 Huntsville, AL 35806 Re: Serina Therapeutics, Inc. Registration Statement on Form S-3 Filed May 22, 2026 File No. 333-296166 Dear Steven Ledger: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen Hinton, Esq.
Show Raw Text
May 29, 2026 Steven Ledger Chief Executive Officer Serina Therapeutics, Inc. 601 Genome Way, Suite 2001 Huntsville, AL 35806 Re: Serina Therapeutics, Inc. Registration Statement on Form S-3 Filed May 22, 2026 File No. 333-296166 Dear Steven Ledger: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen Hinton, Esq.